Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Domino's Pizza, Inc. (DPZ) Price & Performance

AstraZeneca plcTrade
Domino's Pizza, Inc.Trade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Domino's Pizza, Inc. — how do they compare? AstraZeneca plc trades at $157.6 (market cap $248.14B), while Domino's Pizza, Inc. trades at $352.97 (market cap $11.82B). The key difference: AstraZeneca plc is far larger — about 21× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals.

AZNDPZ
Market Cap
$248.14B$11.82B
Sector
HealthConsumer Cyclical
52-Week High
$209.48$467.30
52-Week Low
$147.06$282.89
Enterprise Value
$275.41B$16.78B
Dividend Yield
2.01%2.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

Domino's Pizza, Inc.

Domino's Pizza (DPZ) trades at $347.85, down 0.88% on the day, with mixed technical signals showing neutral overall momentum. The company reported three consecutive quarterly EPS misses but maintains strong profitability with 11.86% net margins and positive revenue growth. Recent news highlights product innovation with the launch of individual-sized pizzas and digital platform enhancements to drive customer engagement.

Wall Street maintains a bullish stance with 54% buy ratings and a $371.67 price target, representing 7% upside potential. Key risks include elevated debt levels, competitive pressures, and consumer spending sensitivity. The stock offers value through consistent dividends and operational efficiency, though near-term execution on sales growth remains critical.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Domino's Pizza, Inc.

Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.

Read more on DPZ